aTyr Pharma ongoing Phase 1b/2 Clinical Trials

aTyr Pharma, a company engaged in the discovery and development of therapeutics to address severe rare disease, is currently conducting two trials of Resolaris (ATYR1940) in patients with rare myopathies with an immune component:

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Study Population</th>
<th>Phase</th>
<th>Study Design</th>
<th>Dosing Regimen</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATYR1940-C-003</td>
<td>Early Onset FSHD Patient age 16 to 25 Symptoms before 10</td>
<td>1b/2</td>
<td>Open-Label, Itra-Patient Dose Escalation Study</td>
<td>Weekly and twice weekly starting at 0.3 mg/kg with potential dose escalation up to 3.0 mg/kg</td>
<td>12 weeks</td>
</tr>
<tr>
<td>ATYR1940-C-004</td>
<td>LGMD2B and FSHD Adult Patients</td>
<td>1b/2</td>
<td>Open-Label, Itra-Patient Dose Escalation Study</td>
<td>Weekly doses starting at 0.3 mg/kg with potential dose escalation up 1.0 mg/kg and 3.0 mg/kg</td>
<td>12 weeks</td>
</tr>
</tbody>
</table>

The trials are designed to assess the safety, tolerability, immunogenicity and activity of Resolaris in patients with the muscular dystrophies of FSHD or limb-girdle muscular dystrophy 2B (LGMD2B or dysferlinopathies). ATYR1940-C-003 is open for enrollment. ATYR1940-C-004 has nearly completed enrollment and is currently closed to screening.

aTyr Pharma recently announced results from its first Phase 1b/2 trial in adult patients with FSHD. To review the press release, please visit the Press section at [www.atyrpharma.com](http://www.atyrpharma.com).

**What is Resolaris (ATYR1940)?**
aTyr Pharma is developing Resolaris as a potential protein therapeutic for patients with severe, rare myopathies with an immune component, for which there are limited or no approved treatments. Resolaris is derived from a naturally occurring protein released in vitro by human skeletal muscle cells. The Company believes Resolaris could potentially play a role in promoting skeletal muscle health by acting as an immunomodulator in skeletal muscle. Inflammation is believed to play a role in the disease process in FSHD and LGMD2B.

For additional information, please visit [www.atyrpharma.com](http://www.atyrpharma.com).

**Where are the trials conducted?**
Clinical sites for both studies are located in the United States and Europe as set forth below.

**ATYR1940-C-003 Study:**
- Stanford University, Palo Alto, California
- University of Iowa Children’s Hospital, Iowa City, Iowa
- University of Utah, Salt Lake City, Utah
- Institut de Myologie, Paris France
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano Italy
ATYR1940-C-004 Study:
University of California, Irvine, ALS and Neuromuscular Center, Irvine, California
Kennedy Krieger Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland
OSU Wexner Medical Center, Columbus, Ohio
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Institut de Myologie, Paris France
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano Italy

Where can I find more information on these trials?
Please visit the following websites to get more detailed information: www.clinicaltrials.gov (type ATYR1940 in “Search studies”) and www.atyrpharma.com.

You can also contact aTyr Pharma by email at clinicaltrials@atyrpharma.com or phone at 1-877-215-5731.

Can I participate in one of these trials?
To be enrolled in the ATYR1940-C-003 study, you should be between 16 and 25 years old, have a genetic confirmation of FSHD and have had onset of FSHD symptoms prior to 10 years of age. You will need to be seen at a participating center.

Some history of other diseases or some medication taken can prevent you from participating in the studies.

Please talk to your doctor about your individual disease status and whether you might be suitable for one of the studies.